# OnCo record paper-keynote-010-lancet-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-keynote-010-lancet-2016" ;
schema:name "KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer"@en ;
schema:description "After chemotherapy had failed, pembrolizumab prolonged life compared with docetaxel in lung cancers expressing any PD-L1, with the largest gain in tumours where at least half the cells were positive, and caused fewer severe side effects."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2016"^^xsd:gYear ;
schema:author "Herbst RS, Baas P, Kim DW, et al." ;
onco:related , , ;
onco:cancers ;
onco:technologies , ;
onco:targets , ;
onco:drugs , ;
onco:companies ;
onco:pathways ;
onco:terms , , ;
onco:people .